Ubiquinol and NMN are both sold as “cellular energy” supplements, often side by side and often to people over fifty. They work at opposite ends of the same machinery, their evidence is very different, and each carries warnings that the packaging rarely mentions. This chapter sets out what each does, what the human studies actually show, who should not take them without talking to a doctor first, and where NMN stands legally in the UK.
1. Two supplements, two ends of the same machinery
Every cell makes its energy in small structures called mitochondria, which turn food into ATP, the molecule cells spend as fuel. Both supplements are aimed at that process, from different directions.
- Coenzyme Q10 works downstream, inside the machine. It sits in the inner membrane of the mitochondria and passes electrons along the chain that makes ATP. It exists in two forms that the body switches between all the time: ubiquinone (oxidised) and ubiquinol (reduced). Ubiquinol is also a fat-soluble antioxidant: it mops up reactive molecules that would otherwise damage cell membranes and the fats carried in the blood. Most of the CoQ10 in your blood is already ubiquinol, whichever form you swallow. Strong
- NMN works upstream, on the supply. Nicotinamide mononucleotide is one step away from NAD+, a molecule every cell needs to turn food into energy and which is also used up by enzymes that repair DNA (PARPs) and by a family of regulatory enzymes called sirtuins, the “longevity genes” of the marketing. NAD+ levels fall with age in many tissues. The idea is that topping up the supply restores those repair and maintenance processes. Strong for the biochemistry; the rest of this chapter is about whether the idea works in people.
| Ubiquinol (active CoQ10) | NMN | |
|---|---|---|
| Where it acts | Downstream: inside the mitochondria, in ATP production, and as an antioxidant | Upstream: raises NAD+, the supply that energy production, DNA repair and sirtuins draw on |
| Sold for | Heart health, stamina, people on statins | Cellular repair, DNA maintenance, “anti-ageing” |
| Best human evidence | One heart-failure trial with fewer cardiac events; inconsistent trials for statin muscle aches | Raises blood NAD+; small, short trials with mixed effects on anything else |
| Main cautions | Warfarin; cancer treatment; possibly diabetes medicines | Active or previous cancer (precautionary); pregnancy; unknown long-term safety |
| UK legal status | Sold freely as a food supplement | Not authorised as a novel food in Great Britain (section 7) |
2. Ubiquinol: what the evidence shows
| Claim | What the evidence shows |
|---|---|
| Statins lower CoQ10 Strong | Statins block an early step in the pathway the body uses to make both cholesterol and CoQ10, and blood CoQ10 falls on them. Whether muscle CoQ10 falls in a way that matters is much less consistent. |
| CoQ10 eases statin muscle aches Contested | Meta-analyses disagree: one of 12 trials (Qu 2018) found less pain; others (Banach 2015, Kennedy 2020) found no benefit, and a 2025 analysis found a small effect with very inconsistent trials. Blinded trials have also shown that most muscle aches reported on statins happen just as often on placebo. NICE’s position (NG238, recommendation 1.12.1): “Do not offer coenzyme Q10 or vitamin D to increase adherence to statin treatment.” Trying it is reasonable; relying on it to make a statin tolerable is not, and aches on a statin are worth raising with your GP, who has other options. |
| CoQ10 helps in heart failure Emerging | One trial, Q-SYMBIO (2014), gave 420 people with heart failure 300 mg a day or placebo for two years. Its short-term measures did not change, but major cardiac events were lower (about 15% against 26%), and so were deaths. It was smaller than planned and has not been repeated. The Cochrane review (2021) found no convincing evidence to support or refute CoQ10 in heart failure, and it is not part of UK or European heart-failure treatment. It is never a substitute for heart-failure medicines. |
| CoQ10 lowers blood pressure Contested | The Cochrane review (2016) found no meaningful fall in blood pressure in the better-quality trials. Earlier, less rigorous trials suggested larger drops. |
| CoQ10 lowers blood sugar Emerging | Pooled trials in diabetes show small falls in HbA1c (about 0.3 percentage points). Small, but relevant if you take insulin or a sulfonylurea (section 3). |
3. Ubiquinol: who should check first
Cancer treatment. Some chemotherapy and radiotherapy work by causing oxidative damage to cancer cells, and there is a concern that antioxidant supplements taken at the same time could blunt that. The evidence is from animal studies and from one large observational study in breast cancer (SWOG S0221, 2020), in which women taking antioxidants, CoQ10 among them, before and during chemotherapy had a higher rate of recurrence that fell just short of statistical significance. It is not proof, but Cancer Research UK and most oncology teams advise against starting antioxidant supplements during treatment without checking with your specialist. Tell your team about anything you take.
Warfarin. CoQ10 is chemically similar to vitamin K, and there are case reports of it weakening warfarin’s effect; a small randomised trial found no change in INR, and one study linked it with more bleeding. The effect is unpredictable, so tell your anticoagulation clinic before starting or stopping it, and have your INR checked. The newer anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) have no known interaction, but tell your pharmacist anyway.
Diabetes and blood-pressure medicines. The small fall in blood sugar (section 2) could add to insulin or a sulfonylurea such as gliclazide, so check your sugars more closely for the first few weeks. Any added effect on blood pressure is probably small or theoretical, but if you feel faint or dizzy on standing, mention it.
Pregnancy and breastfeeding. There is too little safety information. Ask first.
4. Ubiquinol after 50
This is the age group it is most often marketed to, for three reasons, which hold up to different degrees.
- The body’s own CoQ10 falls with age. Tissue levels, including in the heart, decline in later life. Moderate What is not established is that a supplement restores CoQ10 inside the mitochondria of healthy tissue, or that doing so makes people healthier.
- “Older people convert ordinary CoQ10 less well, so they need ubiquinol.” This is mostly a manufacturer’s claim. One study of ten older men found ubiquinol raised blood CoQ10 more than ubiquinone, but without any sign of impaired conversion; another of 21 people aged 65–74 found a well-formulated ubiquinone did better than ubiquinol. The formulation matters as much as the form, and either can be reasonable. Contested
- Many people over 50 take a statin. This is the commonest real reason, and section 2 sets out what it can and cannot be expected to do.
How to take it, if you do. CoQ10 is fat-soluble and poorly absorbed, so take it with a meal that contains some fat, which increases absorption. Moderate Taking it earlier in the day is practical advice rather than evidence: a few people report poor sleep on higher doses, and there are no trials of timing. Trials have used 100–300 mg a day. The cholesterol calculator’s CoQ10 card adjusts its suggestion to whether you take a statin.
5. NMN: what the evidence shows
| Claim | What the evidence shows |
|---|---|
| NMN raises NAD+ Strong | Consistent across a dozen small randomised trials. This is a blood marker; it does not by itself show any benefit, and a 2026 trial of 24 weeks in older adults found sustained rises with “limited” evidence of physiological benefit. |
| NMN improves blood sugar control Emerging | The best-known trial (Yoshino 2021, 25 women with prediabetes, ten weeks) found better insulin sensitivity in muscle on a detailed test, but no change in fasting sugar, HbA1c, blood pressure or body composition. A 2024 meta-analysis found no effect on glucose or HbA1c. |
| NMN improves walking, strength or arteries Emerging | Some small trials report longer walking distances or a trend towards less arterial stiffness, often only in subgroups; reviews find the effects overall are not significant. |
| NMN activates “longevity genes” (sirtuins) Emerging | Shown in cells and animals only. No human study has shown it as a clinical effect. |
| NMN extends life or prevents disease | No human evidence at all. No trial has measured heart attacks, cancer, dementia or death, and the longest have run for about six months. |
6. NMN and cancer: a precaution, not a proven harm
Why there is a concern. Cancer cells, especially fast-growing ones, need large amounts of NAD+, and some animal studies suggest that boosting NAD+ can help an existing tumour. In mice, NMN worsened the inflammatory environment around ageing cells and sped up pancreatic cancer (Nacarelli, 2019); high doses of nicotinamide riboside, a close relative of NMN, increased the growth and brain spread of an aggressive breast cancer (University of Missouri, 2022). Other animal studies point the other way, and there is no human evidence that NMN causes or worsens cancer: the human trials are too short and too small to tell. Emerging
What that means in practice. This is precautionary advice, not a formal guideline:
- If you have cancer now, or are being treated for it, do not take NMN or other NAD+ boosters (NR, NMNH) unless your oncology team agrees.
- If you have had cancer, discuss it with your specialist or GP first.
- If you have a strong family history of cancer, there is no evidence either way. Some clinicians extend the same caution to this group, and it is a reasonable conversation to have with your GP before starting.
Also avoid it in pregnancy and breastfeeding, for which there is no safety information. Doses up to about 1,250 mg a day have been well tolerated in trials of up to six months; beyond that, long-term safety is unknown.
7. NMN’s legal status, as of November 2026
- Great Britain: NMN is classed as a novel food: one without a significant history of being eaten before 1997, which needs a safety assessment and authorisation before it can be sold as a food or food supplement. It has not been authorised; an application is reported to be under assessment. NMN products sold online to UK buyers have therefore not passed that assessment, and their purity and dose are not checked by anyone. The same applies to NMNH, for which no authorisation has been found. (Nicotinamide riboside chloride, a related NAD+ precursor, is authorised.)
- United States: the FDA said in 2022 that NMN could not be sold as a dietary supplement, because it had been investigated as a drug first. It reversed that on 29 September 2025, after a legal challenge, and NMN is again lawful as a supplement there.
- European Union: the European Food Safety Authority judged one manufacturer’s NMN safe for adults at up to 300 mg a day in May 2026 (not in pregnancy or breastfeeding), and member states voted to authorise it in September 2026. It is not legally on sale until that decision is published in the EU’s Official Journal, and the authorisation covers that one product, not NMN in general.
None of this is a judgement on whether NMN works; it is about whether what is in the tub has been checked. This page will be updated when the GB position changes.
8. If you take either anyway
- Tell your GP and pharmacist, and anyone treating you for cancer, heart disease or diabetes. Supplements are medicines as far as interactions are concerned.
- On warfarin: tell the anticoagulation clinic before starting or stopping CoQ10.
- During chemotherapy or radiotherapy: no antioxidant supplements without your specialist’s agreement.
- With active or past cancer: no NMN or other NAD+ boosters without your oncology team’s agreement.
- Do not stop or reduce a statin, blood-pressure or diabetes medicine because you are taking a supplement. None of these replaces them.
- Take CoQ10 with a meal containing fat; earlier in the day if it affects your sleep.
The rest of the frontier tier, and how this site decides what to include, is on the longevity supplements page. Where each claim above comes from is on the reference list.